ACVR1 and breast carcinoma: LDN-193189 is a selective BMP signaling inhibitor that inhibits the kinase activity of ALK2 and the related ALK1 and at a concentration of 1 μM has been shown to also partially and selectively inhibit TGFβ-induced SMAD1/5C phosphorylation in the breast cancer cell line, MDA-MB-231 [11].